Orgenesis, a pioneering, global biotech company committed to lowering costs, accelerating commercialization, and transforming the delivery of cell and gene therapies (CGTs), announced it has entered into an agreement to acquire the assets of Tamir Biotechnology, Inc. ("TamirBio"), including ranpirnase, TamirBio's broad spectrum anti-viral platform.
Mark Cohen, Senior Partner and the Chair of the Life Science Practice Group, represents Orgenesis in its commercial, corporate and intellectual property matters.
To view the slides from this program, please click here.
To watch a full recording, please click here.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
